

Amendments to the Specification

The specification is being amended to correct typographical and clerical errors. No new subject matter is being added.

Please replace the paragraph on page 5, at line 18, with the following rewritten paragraph:

Further the present invention provides for a method ~~of~~ of ameliorating chronic allograft rejection by administering an amount of CSA and 2-CDA effective sufficient to suppress the B-cell mediated response to an allograft. In one embodiment, the allograft organ is a heart and the B-cell mediated response is one or a combination of mononuclear cell infiltration in the myocardium, myocardial fibrosis, and intimal proliferation of smooth muscle cells.

Please replace the paragraph on page 10, at line 7, with the following rewritten paragraph:

In one embodiment, the therapeutically effective amount of ~~2-chlorodeoxyadenosine~~ 2-chlorodeoxyadenosine is between about 0.5 mg and about 3 mg per kilogram of recipient body mass per week. Suitably, the dose of ~~2-chlorodeoxyadenosine~~ 2-chlorodeoxyadenosine is about 1 mg per kilogram of recipient body mass per week, divided into one or more doses per week. In another embodiment, about 1.5 mg of ~~2-chlorodeoxyadenosine~~ 2-chlorodeoxyadenosine per kilogram of allograft recipient body mass is administered about every three weeks in one or more doses. In another embodiment, about 3 mg of ~~2-chlorodeoxyadenosine~~ 2-chlorodeoxyadenosine per kilogram of allograft recipient body mass is administered about every three weeks in one or more doses.

Please replace the paragraph on page 19, at line 5, with the following rewritten paragraph:

Animals were divided into five treatment groups as follows:

**Group      Treatment Regimen**

- A      CSA dosage finding group
- B      5/mg/kg/day CSA; 1-14 days, then 3 times per week for 90 days
- C      1mg/kg/week 2-CDA [D] for 90 days plus 5/mg/kg/day CSA
- D      1mg/kg 2-CDA on days 3, 4, 5, 23, 24, 25, 43, 44, 45, 63, ~~64,65~~, 64, 65, 83, 84 and 85 days post transplant, plus 5/mg/kg/day CSA
- E      0.5 mg/kg 2-CDA on days 3, 4, 5, 23, 24, 25, 43, 44, 45, 63, ~~64,65~~, 64, 65, 83, 84 and 85 days post transplant, plus 5/mg/kg/day CSA

Please replace the paragraph on page 22, at line 5, with the following rewritten paragraph:

A human trial of the use of CSA in combination with 2-CDA in human kidney transplanted patients involves a randomized, prospective, non-blinded study of 150 ~~patients~~ patients. Over a two year period, 100 patients receive 2-CDA in combination with CSA while 50 patients receive other immunosuppression controls. 2-CDA is administered weekly at a dosage based upon clinical trials involving 2-CDA for the treatment of multiple sclerosis and rheumatoid arthritis. Dosage can be administered subcutaneously or orally. ~~Concominant~~ Concomitant immunosuppression with cyclosporin is administered. Control patients are placed on or maintained on cyclosporin and prednisone therapy at doses determined as optimal for each patient based upon known protocols.